Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study.

Heinz-Peer, Gertraud; Schoder, Maria; Rand, Troy; Mayer, Gert; Mostbeck, G.

doi:10.1148/radiology.195.3.7753991

Cited by 88 publications

(59 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median time from transplant to development of any renal cancer was 4.5 years for RCC and 2.1 years for TCC. Although other studies have demonstrated that a higher proportion of tumors occur in the native kidney, 12,13 our results demonstrate that the median times for development of both RCC and TCC in the native kidney were much shorter than in the allograft. In contrast to our findings, other studies have shown a longer median time of 3.9 to 7.4 years for development of RCC and 4.4 to 4.8 years for TCC after renal transplant.…”

Section: Discussioncontrasting

confidence: 74%

Untitled

Ranasinghe

Suh²,

Hughes³

2016

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Our objective was to determine the incidence and outcomes of renal cell carcinoma and transitional cell carcinoma in recipients of renal allografts. Materials and Methods:We analyzed data from 2000 to 2012 in the Australia and New Zealand Dialysis and Transplant Registry, a binational population-based database, to identify the incidence and survival outcomes of renal transplant recipients with renal cell and transitional cell carcinoma. Results: Of the 8850 renal transplants, there were 60 new diagnoses of renal cancers posttransplant, with an overall cumulative incidence of 56 per 100 000 per year. Nine tumors were detected in the allograft, and 51 tumors (85%) were detected in the native kidney of the recipient. The median time of diagnosis from transplant was 6.6 years (range, 0.1-8.9 y). There were no cancerspecific deaths from allograft tumors; however, 17 cancer-specific deaths (14 from renal cell carcinoma and 3 from transitional cell carcinoma) occurred in patients with cancer in the native kidney. The 5-year and 10-year cancer-specific survival rates for renal cell carcinoma were 71.2% (95% confidence interval (CI): 57.0-84.0) and 58.5% (95% CI: 40.5-77.9), with 5-year and 10-year rates for transitional cell carcinoma of 50% (95% CI: 15.5-94.2) and 0%. Conclusions: Renal cell carcinoma occurring in the native kidney comprised most of the tumors detected after renal transplant; however, transitional cell carcinoma occurred sooner after transplant and resulted in a lower cancer-specific survival rate. While it is important to screen those at risk of TCC prior and after renal transplant, the low incidence of TCC maybe too small to justify a benefit with routine screening, compared to RCCs.

show abstract

Section: Discussioncontrasting

confidence: 74%

Untitled

Ranasinghe

Suh²,

Hughes³

2016

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…Schwarz et al (9) reported a relatively high prevalence of RCC in kidney transplant patients with ACKD. Therefore, they concluded that ACKD was a risk factor for RCC among kidney transplant recipients and screening such as ultrasound should be performed for RCC in such patients, which consistent with study of Heinz-Peer et al (10) reported a high prevalence of RCC in patients undergoing kidney transplantation.…”

Section: Implication For Health Policy/practice/research/medical Educsupporting

confidence: 68%

Are acquired cystic kidney disease and autosomal dominant polycystic kidney disease risk factors for renal cell carcinoma in kidney transplant patients?

Einollahi¹

2012

J Nephropathol

View full text Add to dashboard Cite

“…In this study, in all but one patient kidney neoplasms were detected over 5 years after renal transplantation, with tumor sizes ranging from 16 to 35 mm. Assuming a growth rate of renal carcinomas in allotransplanted patients of 0.5-1 .O cm/year, these tumors had to originate after kidney transplantation [4]. It has been shown that none of the patients, neither kidney recipients nor any from the control group, had local disease recurrence or distant metastasis in a median of almost 3 years after radical treatment.…”

Section: Discussionmentioning

confidence: 99%

A matched case-control study on the prognosis of native kidney neoplasia in renal transplant recipients

et al. 2002

View full text Add to dashboard Cite

A matched case-control study on the prognosis of native kidney neoplasia in renal transplant recipientsAbstract A matched case-control study was performed to compare the prognosis of six renal transplant recipients with a control group of nontransplant patients, both groups presenting with native kidney tumors. Patients were matched for age, gender, neoplasm histology, and TNM classification. The follow-up ranged from 8 to 131 months (median 32 months) after nephrectomy or nephroureterectomy of the native kidney. Five out of six recipients retained good graft function. No evidence of recurrent local disease or distant metastasis of kidney neoplasms was observed in either group.

show abstract

Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study.

Abstract: The frequency of ACKD increases with the duration of hemodialysis. The risk for the development of ACKD is increased in men and older patients. The malignant potential of ACKD persists after renal transplantation.

Cited by 88 publications

References 0 publications

Untitled

Untitled

Are acquired cystic kidney disease and autosomal dominant polycystic kidney disease risk factors for renal cell carcinoma in kidney transplant patients?

A matched case-control study on the prognosis of native kidney neoplasia in renal transplant recipients

Contact Info

Product

Resources

About